[ad_1] AstraZeneca Plc (LON:AZN) announced today positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin). The data were presented as a late-breaking abstract (#19485) at the …
Read More »AstraZeneca Plc Farxiga significantly reduced hospitalisation for heart failure or CV death
